Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer

Oncology Reports

Volumn 13, Issue 6, 2005, Pages 1153-1158

  Kusuda, Tomoyo ^a   Shigemasa, Kazushi ^a   Arihiro, Koji ^a,b   Fujii, Tsuneo ^b   Nagai, Nobutaka ^a   Ohama, Koso ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

mRNA; Ovarian cancer; Real time PCR; Th1; Th2

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 6; MESSENGER RNA; PROTEIN SUBUNIT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYSTADENOCARCINOMA; FEMALE; GENETICS; HUMAN; METABOLISM; NEOPLASM; OVARY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL;

CYSTADENOCARCINOMA, SEROUS; DNA, COMPLEMENTARY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-6; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24744454001     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.6.1153     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 46: 5-27, 1996.
2. Wanidworanun C and Strober W: Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 151: 6853-6861, 1993. (Pubitemid 24001060)
3. Schulze-Koops H and Kalden JR: The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 15: 677-691, 2001. (Pubitemid 34092508)
4. Tang L, Benjaponpitak S, DeKruyff RH and Umetsu DT: Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production. J Allergy Clin Immunol 102: 428-435, 1998. (Pubitemid 28471503)
5. Maggi E: The TH1/TH2 paradigm in allergy. Immunotechnology 3: 233-244, 1998.
6. Kidd P: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8: 223-246, 2003.
7. Mosmann TR and Sad S: The expanding universe of T-cell subsets: Th1,Th2 and more. Immunol Today 17: 138-146, 1996. (Pubitemid 26074503)
8. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027, 1994.
9. Nishimura T, Watanabe K, Lee U, et al: Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor. Immunol Lett 48: 149-152, 1995. (Pubitemid 26014800)
10. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM and Lotze MT: Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21: 339-359, 1999. (Pubitemid 30011443)
11. Huang M, Wang J, Lee P, et al: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55: 3847-3853, 1995.
12. Aoki Y, Tsuneki I, Sasaki M, et al: Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest 50: 207-211, 2000.
13. Goto S, Sato M, Kaneko R, Itoh M, Sato S and Takeuchi S: Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48: 435-442, 1999. (Pubitemid 29503443)
14. Zeimet AG, Widschwendter M, Knabbe C, et al: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868, 1998. (Pubitemid 28234733)
15. Punnonen R, Teisala K, Kuoppala T, Bennett B and Punnonen J: Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 83: 788-796, 1998. (Pubitemid 28387706)
16. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME: Apoptosis signaling by death receptors. Eur J Biochem 254: 439-459, 1998. (Pubitemid 28308094)
17. Old LJ: Tumour necrosis factor. Another chapter in the long history of endotoxin. Nature 330: 602-603, 1987.
18. Hernandez-Pando R and Rook GA: The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82: 591-595, 1994.
19. Rubin SC, Hoskins WJ, Markman M, Federici M, Lloyd KO and Lewis JL Jr: Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer. Gynecol Oncol 34: 353-356, 1989. (Pubitemid 19218577)
20. Cuello M, Ettenberg SA, Nau MM and Lipkowitz S: Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390, 2001. (Pubitemid 32494651)
21. Gubler U, Chua AO, Schoenhaut DS, et al: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143-4147, 1991. (Pubitemid 21914495)
22. Brunda MJ and Gately MK: Interleukin-12: potential role in cancer therapy. Important Adv Oncol 3-18, 1995.
23. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994. (Pubitemid 24251114)
24. Lenzi R, Rosenblum M, Verschraegen C, et al: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8: 3686-3695, 2002. (Pubitemid 35428817)
25. Malik ST, Knowles RG, East N, Lando D, Stamp G and Balkwill FR: Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 51: 6643-6649, 1991.
26. Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561, 1998. (Pubitemid 28293291)
27. Ogawa M, Yu WG, Umehara K, et al: Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression. Cancer Res 58: 2426-2432, 1998. (Pubitemid 28252704)
28. Pujade-Lauraine E, Guastalla JP, Colombo N, et al: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14: 343-350, 1996. (Pubitemid 26050993)
29. Welander CE, Homesley HD, Reich SD and Levin EA: A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 11: 465-469, 1988.
30. Maluish AE, Urba WJ, Longo DL, et al: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434-445, 1988. (Pubitemid 18090689)
31. Windbichler GH, Hausmaninger H, Stummvoll W, et al: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: 1138-1144, 2000. (Pubitemid 30128869)
32. Offner FA, Obrist P, Stadlmann S, et al: IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7: 542-547, 1995.
33. Motro B, Itin A, Sachs L and Keshet E: Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87: 3092-3096, 1990.
34. Tanner J and Tosato G: Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239-247, 1991.
35. Scambia G, Testa U, Panici PB, et al: Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 57: 318-323, 1994. (Pubitemid 24168603)
36. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM and Martinez-Maza O: Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164: 1038-1042, 1991.
37. Gastl G, Plante M, Finstad CL, et al: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 83: 433-441, 1993. (Pubitemid 23080014) Technology